| ●Editorial | Yamada H，Kita K | 132-3 | Full text | |
| ●Research Meeting and Webinar on Cutaneous Leishmaniasis (CL): Research and development for neglected diseases and associated social issues | 135-234 | Abstract | ||
| ※Webinar information | ||||
| Agenda and Profiles | 138-47 | Full text | ||
| ・Part 1 Cutaneous Leishmaniasis (CL) Research Meeting | ||||
| Welcome Address and Opening Remarks | Hirabayashi F，Nakatani K，Kita K | 148-9 | ||
| Cutaneous Leishmaniasis: Current situation and DNDi’s approach | Arana B | 150-7 | Summary | |
| Preclinical development of CpG D35 for combined treatment of cutaneous leishmaniasis | Ishii KJ | 158-67 | Summary | |
| Prospects for new treatments for leishmaniasis | Mowbray C | 168-76 | Summary | |
| CL Treatment Strategy: The vision and pathway to access | Ajose O | 177-81 | Summary | |
| A live attenuated markerless prophylactic vaccine for leishmaniasis using CRISPR gene editing | Hamano S | 182-6 | Summary | |
| Q&A | 187-9 | |||
| Closing Remarks | Yamada H | 190 | ||
| ・Part 2 Webinar: Cutaneous Leishmaniasis (CL) | ||||
| Welcome Address | Hirabayashi F | 191 | ||
| Cutaneous Leishmaniasis in conflict situations | Ritmeijer K | 192-200 | Summary | |
| Cutaneous leishmaniasis and mental health: Exploring psychosocial impact and CL-associated stigma (the ECLIPSE programme) | Dikomitis L，Price H，et al． | 201-9 | Summary | |
| Cutaneous Leishmaniasis (CL) in women and children | Bennis I | 210-6 | Summary | |
| Cutaneous Leishmaniasis: Current treatments and gaps | Arana B | 217-24 | Summary | |
| Current approaches to the development of a vaccine against CL | Goto Y | 225-32 | Summary | |
| Q&A and Closing Remarks | van Gulik C，Hirabayashi F，Kita K | 233-4 | ||
| ●Articles | ||||
| Antimalarial drug candidate showing anti-new coronavirus effects: Diverse developments in infectious disease research | Kita K | 235-42 | Abstract | |
| A landmark proposal in the COVID-19 pandemic: Why is the TRIPS waiver important? | Kurumiya T，Kanasugi U | 243-52 | Abstract | |
| Placebo drift revisited: Reviewing placebo response mitigation | Saio T，Kurihara C | 253-62 | Full text | |
| ●Lecture | ||||
| Ongoing paradigm shift in BioHealth science and technology | Fukushima M | 263-82 | Abstract | |
| ●Explanatory article and translation | ||||
| Guiding Principles on Reasonable Agreements between Patient Advocates and Pharmaceutical Companies －Translation of the materials and its potential for future application－ | Imamura K，Saeki H， Nakahama H，Tsukahara K， Tsutsumi N，Kurihara C |
283-9 | Abstract | |
| Guiding Principles on Reasonable Agreements between Patient Advocates and Pharmaceutical Companies | Trans. by Tsukahara K，Tsutsumi N， Nakahama H Trans. & Superviser: Imamura K， Kurihara C，Saeki H， Mimura M，Nemoto T，Obata M， Iwasaki K，Abe Y | 291-304 | Full text | |
| ●Forum | ||||
| A group of Patient Public Involvement (PPI) shared their feelings after reading “DECLARATION OF HELSINKI”: Part 2 The launch of developing “MY/OUR DECLARATION OF HELSINKI” | Yoshikawa K，Saeki H， Tsutsumi N，et al． |
305-14 | Full text | |
| Heart plus help mark/Satchan’s mom | Takagi Y | 315-7 | Full text | |
| The 12th Annual Meeting of the Japanese Association of Pharmaceutical Medicine 2021－A new style of pharmaceutical medicine | Matsuyama K | 319-24 | Full text | |
| ●Instructions for authors［Japanese］＆［English］ | 325-33 | Full text | ||
| ●Editor’s note | Saio T | 335 | Full text | |